-
Pfizer Lung Drug Stops Deadly Child Cancers in Study
Monday, May 21, 2012
Pfizer Inc.’s Xalkori, a drug that targets lung cancer caused by a gene defect, wiped out all signs of malignancy in some children with different tumor types, in a study that proves aiming treatment at genes rather than disease sites may be more effectiveThe findings, being released today in adv
-
Telik Announces the Publication of Two Reports in the Journal of Hematology & Oncology
Monday, May 21, 2012
PALO ALTO, Calif. - Telik, Inc. announced two publications in the Journal of Hematology & OncologyThe first is "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)," Raz
-
Analysis of Rilotumumab Data Identifies a Potential Predictive Biomarker for Patients With Gastric or Gastroesophageal Cancer
Monday, May 21, 2012
THOUSAND OAKS, Calif. - Amgen announced results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumabThis analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric
-
Amgen's BiTE Antibody Blinatumomab Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Monday, May 21, 2012
THOUSAND OAKS, Calif. - Amgen announced updated results from a Phase 2 study that showed treatment with blinatumomab helped achieve a high-rate of complete response in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia treated in the studyBlinatumomab
-
Intellect Neurosciences Expands Its Immunotherapy Pipeline With New Technology Platforms Targeting Pathogenic Protein Aggregates Focused on Huntington's and Parkinson's Diseases
Monday, May 21, 2012
NEW YORK - Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseasesannounced it has filed three new patent applications with the United States Patent
-
MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in Vitro Models
Monday, May 21, 2012
WOONSOCKET, R.I. - MultiCell Technologies, Inc. is pleased to announce representatives from the Company will present preclinical research findings for MCT-465 and MCT-485 at CIMT 2012, Europe's largest meeting dedicated to cancer immunotherapy research and developmentCIMT 2012 will be held in May
-
Arno Gains Orphan-drug Status for AR-42 in Europe
Friday, May 18, 2012
Arno Therapeutics has received orphan-drug designation for AR-42 to treat neurofibromatosis type 2 (NF2) in the EuropeAR-42 is a broad-spectrum deacetylation inhibitor of both histone and non-histone proteinsThe orally available inhibitor has demonstrated greater potency and activity in solid tum
-
Novartis NVA237 Phase III Data Showed Rapid, Sustained Improvement in Lung Function and Symptom Relief Over One Year in COPD Patients
Friday, May 18, 2012
Basel - Results from the pivotal Phase III GLOW2 study demonstrated that once-daily (QD) 50 mcg NVA237 (glycopyrronium bromide) was superior to placebo in improving lung function, symptom relief and quality of life, and reducing exacerbations over a one-year periodThe data will be presented at the
-
Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug Application for CEP-32496, a Novel BRAF Inhibitor
Friday, May 18, 2012
SAN DIEGO and JERUSALEM - Ambit Biosciences and Teva Pharmaceutical Industries Limited announced the clearance of an Investigational New Drug application with the U.S. Food and Drug Administration for CEP-32496, a novel BRAF kinase inhibitorThe IND filing was based upon promising therapeutic pot
-
Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting
Friday, May 18, 2012
Lund, Sweden and Paris, France - Active Biotech and Ipsen will present tasquinimod, their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago on 1-5 June 2012The presentation will provide overall survival data from the tasquinimod Phase II